ExploreWatchlistsPricing
  1. US-listed companies
  2. LIGAND PHARMACEUTICALS INC
  3. Financials
  4. Net income

LIGAND PHARMACEUTICALS INC (LGND)

Market cap
$4.7B
P/E ratio
38.2x
SummaryFinancials
Period EndNet income (Million USD)YoY (%)
Dec 31, 2025124-3186.63%
Dec 31, 2024-4-107.73%
Dec 31, 202352-256.33%
Dec 31, 2022-33-158.39%
Dec 31, 202157-2014.17%
Dec 31, 2020-3-100.47%
Dec 31, 2019629+339.09%
Dec 31, 2018143+1041.45%
Dec 31, 201713-867.48%
Dec 31, 2016-2-100.64%
Dec 31, 2015257+2039.93%
Dec 31, 201412+5.29%
Dec 31, 201311-2266.98%
Dec 31, 2012-1-105.18%
Dec 31, 201110

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat